TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38194233

Group type: EXPERIMENTAL
Intervention: Curative-intent therapy for colorectal cancer
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-General (rapid version) score increase
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-efficacy increase
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Neighborhood deprivation index
Number of subjects: 450
Study: 38194236

Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation (CR) - 10 center-based supervised exercise sessions plus counseling in 4 to 6 weeks, followed by support at home via telephone calls and text messages through weeks 8 to 12.
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (CR) - 18 to 22 sessions with exercises and education in 8 to 12 weeks.
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation (CR)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (CR)
Number of subjects: 191
Study: 38194247

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) scenario followed by an educational video and a repetition of the VR scenario; duration: not specified.
Number of subjects: 15
Study: 38194257

Group type: EXPERIMENTAL
Intervention: Voice warning during simulated driving (Study 0)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Voice warning during driving with T1DM participants (Study 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Voice warning during real-world driving with T1DM participants (Study 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Voice warning across all studies
Number of subjects: 48
Study: 38194272

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (5 doses over 28 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline (NS) control
Number of subjects: 21
Study: 38194603

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation combined with Alternating Synchronized and Nonsynchronized Intermittent Theta Burst Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38194610

Group type: EXPERIMENTAL
Intervention: Individualized risk-prediction model (IRMMa)
Number of subjects: 1933

Group type: COMPARATOR
Intervention: International Staging System (ISS)
Number of subjects: 1933

Group type: COMPARATOR
Intervention: Revised-ISS
Number of subjects: 1933

Group type: COMPARATOR
Intervention: R2-ISS
Number of subjects: 1933
Study: 38194613

Group type: EXPERIMENTAL
Intervention: NROSS screening (two-stage screening strategy with CA-125 and TVS)
Number of subjects: 7856

Group type: EXPERIMENTAL
Intervention: NROSS screening
Number of subjects: 7856
Study: 38194616

Group type: EXPERIMENTAL
Intervention: Adjuvant Abemaciclib plus endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (endocrine therapy alone)
Number of subjects: 0
Study: 38194689

Group type: EXPERIMENTAL
Intervention: RAC2 mutations (23 distinct mutations, including 15 novel variants)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: RAC2 mutations
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: RAC2 mutant proteins
Number of subjects: 54
Study: 38194692

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion (0.6 × 10^8-6 × 10^8 chimeric antigen receptor-positive viable T cells)
Number of subjects: 97
Study: 38195076

Group type: EXPERIMENTAL
Intervention: Concurrent tumor-treating fields (TTFields) with radiation and temozolomide
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment after recurrence
Number of subjects: 1
Study: 38195162

Group type: EXPERIMENTAL
Intervention: Adult male offspring of AAA patients
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Adult female offspring of AAA patients
Number of subjects: 943

Group type: COMPARATOR
Intervention: Male controls
Number of subjects: 943

Group type: COMPARATOR
Intervention: Female controls
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Male adult offspring of AAA patients
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Female adult offspring of AAA patients
Number of subjects: 943
Study: 38195170

Group type: EXPERIMENTAL
Intervention: Screening arm (MRI combined with targeted biopsies)
Number of subjects: 111000

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 111000

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 111000
Study: 38195171

Group type: EXPERIMENTAL
Intervention: Purrble robot intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 168
Study: 38195172

Group type: EXPERIMENTAL
Intervention: Clinical assessment including endoscopy with duodenal biopsies
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Screening for CD by serology
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Linkage to hospital records and the Norwegian Patient Registry (NPR)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Follow-up assessment after at least 1 year including repeated standard serological testing, endoscopy and tissue sampling
Number of subjects: 853
Study: 38195322

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (intravenous) - 1 mg on Day 1, 2 mg on Day 8, 60 mg on Day 15/Cycle 2 Day 1, and 30 mg from Cycle 3 Day 1 onwards for a median of eight 21-day cycles.
Number of subjects: 218
Study: 38195348

Group type: EXPERIMENTAL
Intervention: 150-mg IV infusion of lefamulin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 600-mg oral tablet of lefamulin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison with prior studies in healthy volunteers
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 13
Study: 38195390

Group type: EXPERIMENTAL
Intervention: Women with concerns about COVID-19
Number of subjects: 1478

Group type: COMPARATOR
Intervention: Women without concerns about COVID-19
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 1478
Study: 38195396

Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT)
Number of subjects: 554
Study: 38195438

Group type: EXPERIMENTAL
Intervention: Medial supraclavicular lymph node irradiation (M-SCLI)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Medial plus posterolateral supraclavicular lymph node irradiation (entire SCL irradiation, E-SCLI)
Number of subjects: 1650
Study: 38195471

Group type: EXPERIMENTAL
Intervention: Psychoneurological symptom cluster assessment using network analyses at baseline, 6, 12, and 24 months.
Number of subjects: 480
Study: 38195473

Group type: EXPERIMENTAL
Intervention: Black Impact community-based lifestyle change program
Number of subjects: 74
Study: 38195486

Group type: EXPERIMENTAL
Intervention: eHealth device (n=36)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No eHealth device (n=34)
Number of subjects: 70
Study: 38195550

Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (RC) levels in quartiles
Number of subjects: 5597

Group type: EXPERIMENTAL
Intervention: Discordant high RC/low LDL-C group
Number of subjects: 5597
Study: 38195568

Group type: EXPERIMENTAL
Intervention: Dietary sulfur amino acid restriction (SAAR) ~ 2 g/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group ~ 5.6 g/day sulfur amino acids
Number of subjects: 59
Study: 38195586

Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intravenous aspirin
Number of subjects: 240
Study: 38195600

Group type: EXPERIMENTAL
Intervention: HEARTS-aligned components including training health workers, strengthening access to medications, risk-based management, team-based care, and electronic monitoring.
Number of subjects: 100
Study: 38195605

Group type: EXPERIMENTAL
Intervention: Anodal brain stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal brain stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral brain stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Upper Extremity (FM-UE) score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subset of FM-UE (A) related to muscle synergies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale
Number of subjects: 0
Study: 38195728

Group type: EXPERIMENTAL
Intervention: Leukoreduced packed red blood cell (PRBC) transfusion
Number of subjects: 23
Study: 38195732

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (without periodontal disease)
Number of subjects: 70
Study: 38195752

Group type: EXPERIMENTAL
Intervention: Amph-Peptides-2P and Amph-CpG-7909
Number of subjects: 25
Study: 38195922

Group type: EXPERIMENTAL
Intervention: Nadir-to-regain time ≤1 day
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Cumulative weight loss ≤-50 percent-days
Number of subjects: 654
Study: 38195921

Group type: EXPERIMENTAL
Intervention: OFC growth failure in-hospital
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: OFC growth failure at 2 years
Number of subjects: 590
Study: 38196014

Group type: EXPERIMENTAL
Intervention: Difelikefalin
Number of subjects: 222
Study: 38196092

Group type: EXPERIMENTAL
Intervention: Smoking (daily and occasional)
Number of subjects: 42935

Group type: EXPERIMENTAL
Intervention: Snus use
Number of subjects: 42935

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 42935

Group type: EXPERIMENTAL
Intervention: Tobacco use (daily, occasional, and snus)
Number of subjects: 42935

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 42935
Study: 38196118

Group type: EXPERIMENTAL
Intervention: CART-I Plus
Number of subjects: 33

Group type: COMPARATOR
Intervention: ABPM
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CART-I Plus and ABPM
Number of subjects: 33
Study: 38196129

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study: 38196286

Group type: EXPERIMENTAL
Intervention: Dual Antiplatelet Therapy
Number of subjects: 0
Study: 38196458

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 220

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 220
Study: 38196617

Group type: EXPERIMENTAL
Intervention: Training in the blind field
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Training in the intact field
Number of subjects: 48
Study: 38196639

Group type: EXPERIMENTAL
Intervention: TFC+ISF+P4P (financial incentives for MIBI implementation)
Number of subjects: 428

Group type: COMPARATOR
Intervention: TFC+ISF (control condition)
Number of subjects: 428
Study: 38196650

Group type: EXPERIMENTAL
Intervention: Mind-body intervention as an adjunct to MOUD
Number of subjects: 303

Group type: COMPARATOR
Intervention: MOUD (standard treatment)
Number of subjects: 303
Study: 38196655

Group type: EXPERIMENTAL
Intervention: Home visit plus one-time economic incentive
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Short-term counseling and economic incentive program
Number of subjects: 1332
Study: 38196756

Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched treatment (PET) lettuce
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control lettuce
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control and PET lettuce
Number of subjects: 42
Study: 38196889

Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg every 4 weeks for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study: 38196940

Group type: EXPERIMENTAL
Intervention: Gait asymmetry in spatiotemporal and kinetic variables
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Leg length discrepancy and fat mass as determinants of asymmetry
Number of subjects: 836
Study: 38196969

Group type: EXPERIMENTAL
Intervention: Clinical hypnosis (n = 45)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Treatment-as-usual (n = 47)
Number of subjects: 92
Study: 38197000

Group type: EXPERIMENTAL
Intervention: Sustained-release pregabalin tablet (YHD1119), once-daily dosing.
Number of subjects: 0
Study: 38197040

Group type: EXPERIMENTAL
Intervention: Qualitative understanding of experiences related to cancer cachexia (CC) through semi-structured interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment recommendations by oncologist for anorexia and weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall experience of anorexia and weight loss
Number of subjects: 0
Study: 38197138

Group type: EXPERIMENTAL
Intervention: sitravatinib plus tislelizumab
Number of subjects: 0
Study: 38197225

Group type: EXPERIMENTAL
Intervention: Morning dry mouth
Number of subjects: 1291
Study: 38197296

Group type: EXPERIMENTAL
Intervention: Xevinapant plus radiotherapy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo plus radiotherapy
Number of subjects: 700
Study: 38197636

Group type: EXPERIMENTAL
Intervention: Extended vital sign checks (EVs) from every 4 hours to every 6 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caregiver-reported sleep disturbance
Number of subjects: 50
Study: 38197642

Group type: EXPERIMENTAL
Intervention: Frail patients (mFI ≥2)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Nonfrail patients (mFI = 0-1)
Number of subjects: 261
Study: 38197815

Group type: EXPERIMENTAL
Intervention: Repotrectinib (160 mg daily for 14 days, then 160 mg twice daily)
Number of subjects: 71
Study: 38197817

Group type: EXPERIMENTAL
Intervention: 500-mg daily dose of calcium supplementation
Number of subjects: 11000

Group type: COMPARATOR
Intervention: 1500-mg daily dose of calcium supplementation
Number of subjects: 11000
Study: 38197816

Group type: EXPERIMENTAL
Intervention: Acoramidis hydrochloride at a dose of 800 mg twice daily
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study: 38197863

Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis of indeterminate potential (CHIP) identified among PWH
Number of subjects: 4486

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4486

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4486

Group type: EXPERIMENTAL
Intervention: Geographic origin (outside North America)
Number of subjects: 4486

Group type: EXPERIMENTAL
Intervention: Hispanic/Latino ethnicity
Number of subjects: 4486

Group type: EXPERIMENTAL
Intervention: CD4 nadir <50 cells/mm3
Number of subjects: 4486

Group type: EXPERIMENTAL
Intervention: Short duration of antiretroviral therapy (ART)
Number of subjects: 4486
Study: 38197938

Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine (Ven/Aza) maintenance therapy: Aza 36 mg/m2 intravenously on days 1 to 5, and Ven 400 mg by mouth on days 1 to 14 (42-day cycles × 8, or 28-day cycles × 12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine (Ven/Aza) maintenance therapy
Number of subjects: 27
Study: 38197947

Group type: EXPERIMENTAL
Intervention: Virtual reality sessions (6 sessions with Nintendo Switch)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional rehabilitation sessions only
Number of subjects: 58
Study: 38198010

Group type: EXPERIMENTAL
Intervention: HRS-2261 (25, 100, 200, 400, 800, and 1200 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: HRS-2261 (50, 200, and 400 mg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 38198053

Group type: EXPERIMENTAL
Intervention: Proactive intravitreal aflibercept (IVT-AFL) treatment regimens (fixed dosing or treat-and-extend)
Number of subjects: 1466
Study: 38198106

Group type: EXPERIMENTAL
Intervention: Carglumic acid treatment for at least 1 year
Number of subjects: 10
Study: 38198141

Group type: EXPERIMENTAL
Intervention: Short-stay unit (SSU) care
Number of subjects: 194

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 194
Study: 38198456

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Therapy with placebo
Number of subjects: 90
Study: 38198792

Group type: EXPERIMENTAL
Intervention: Estimated Glucose Disposal Rate (eGDR)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Lowest eGDR tertile (highest level of IR)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic clamp (HEC)
Number of subjects: 287
Study: 38199147

Group type: EXPERIMENTAL
Intervention: Nivolumab + cyclophosphamide and vinblastine (arm A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nivolumab + capecitabine (arm B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nivolumab + cyclophosphamide, vinblastine and capecitabine (arm C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 16
Study: 38199288

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study: 38199593

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 521

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 521
Study: 38199617

Group type: EXPERIMENTAL
Intervention: Oral challenge with one of two strains of non-typhoidal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 38199626

Group type: EXPERIMENTAL
Intervention: Concerns about stopping score (measured using the rPATD questionnaire)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Agreement with deprescribing
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Implementation of prescribing recommendations from the OPTICA medication review
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Change in the number of long-term medications
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Change in medication appropriateness (Medication Appropriateness Index)
Number of subjects: 298
Study: 38199628

Group type: EXPERIMENTAL
Intervention: Muscle Strengthening Training (MST) for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Behavioural Graded Activity (BGA) for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 90
Study: 38199634

Group type: EXPERIMENTAL
Intervention: HOW R U? weekly volunteer-peer support telephone intervention
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HOW R U? delivered using a video-conferencing solution
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 141
Study: 38199635

Group type: EXPERIMENTAL
Intervention: Extended pancreatic neck transection
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conventional pancreatic neck transection
Number of subjects: 154
Study: 38199637

Group type: EXPERIMENTAL
Intervention: BCAN-RAY risk assessment strategy
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Semistructured interviews
Number of subjects: 750
Study: 38199641

Group type: EXPERIMENTAL
Intervention: Multiple assessment modalities for physical function
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Wearable sensor and patient-centred health data aggregating platform
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Longitudinal physical function assessments
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Feasibility of multimodal physical function data collection
Number of subjects: 200
Study: 38199751

Group type: EXPERIMENTAL
Intervention: Target lesion revascularization (TLR) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Presence of TLR
Number of subjects: 1397
Study: 38199789

Group type: EXPERIMENTAL
Intervention: Group A (single round of ovarian stimulation with hCG triggering)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Group B (two uninterrupted rounds of ovarian stimulation with GnRH agonist triggering)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of cumulative outcomes between Group A and Group B
Number of subjects: 46
Study: 38199870

Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2157
Study: 38200171

Group type: EXPERIMENTAL
Intervention: Microneedling radiofrequency (RF) treatment continued monthly over 6 months after 2 months of conventional therapy.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated side (control group).
Number of subjects: 15
Study: 38200233

Group type: EXPERIMENTAL
Intervention: DFMO (up to 9000 mg/m) with celecoxib, cyclophosphamide, and topotecan
Number of subjects: 24
Study: 38200320

Group type: EXPERIMENTAL
Intervention: Aflibercept 0.4 mg/eye
Number of subjects: 113

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 113
Study: 38200325

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5-1 mcg/kg intravenously
Number of subjects: 324

Group type: COMPARATOR
Intervention: Isotonic saline solution intravenously
Number of subjects: 324
Study: 38200410

Group type: EXPERIMENTAL
Intervention: Monoimmunotherapy (Arm A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy followed by monoimmunotherapy (Arm B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XELIRI six cycle regime (Arm C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX nine cycle regime (Arm D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Watch and wait (W&W) strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 0
Study: 38200419

Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Sustained virologic response (SVR)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (gender, age, income, genotype)
Number of subjects: 456
Study: 38200486

Group type: EXPERIMENTAL
Intervention: Micro-choice based concentrated group rehabilitation
Number of subjects: 241
Study: 38200581

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg daily)
Number of subjects: 63
Study: 38200621

Group type: EXPERIMENTAL
Intervention: Estimated pulse-wave velocity (ePWV)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Each m·s-1 increase in ePWV
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: ePWV
Number of subjects: 15773